Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Active not recruiting 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Lymphoid 1

Conditions

Hodgkin Disease 47Lymphoma 22Lymphoma, Non-Hodgkin 18Lymphoma, Large B-Cell, Diffuse 15Multiple Myeloma 12Melanoma 9Lymphoma, B-Cell 9Leukemia, Lymphocytic, Chronic, B-Cell 9Hematologic Neoplasms 9Lymphoma, Follicular 7Myelodysplastic Syndromes 5Mycosis Fungoides 5Lymphoma, T-Cell, Peripheral 5Lymphoma, T-Cell 5Lymphoma, Large-Cell, Anaplastic 5Carcinoma, Renal Cell 5Burkitt Lymphoma 5Uterine Cervical Neoplasms 4Recurrence 4Precursor Cell Lymphoblastic Leukemia-Lymphoma 4Neoplasm Metastasis 4Lymphoma, T-Cell, Cutaneous 4Lymphoma, B-Cell, Marginal Zone 4Colorectal Neoplasms 4Carcinoma, Merkel Cell 4Breast Neoplasms 4Stomach Neoplasms 3Squamous Cell Carcinoma of Head and Neck 3Small Cell Lung Carcinoma 3Pancreatic Neoplasms 3

Interventions

Etoposide 6Vincristine 5Prednisone 5Doxorubicin 5Cyclophosphamide 5Rituximab 4prednylidene 3deltacortene 3daratumumab 2Cytarabine 2varlilumab 1pomalidomide 1merphos 1ixazomib 1carmustine, poliferprosan 20 drug combination 1belantamab mafodotin 1Vorinostat 1Specimen Handling 1Peripheral Blood Stem Cell Transplantation 1Nivolumab 1Methotrexate 1Melphalan 1Magnetic Resonance Spectroscopy 1Immunoglobulin G 1Hydrocortisone 1Disulfides 1Dexamethasone 1Carmustine 1CT-P10 1Bortezomib 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Plasmablastic Lymphoma × Nivolumab × Lymphoid × Clear all
NCT03038672 2026-05-12

Nivolumab With or Without Varlilumab in Treating Patients With Relapsed or Refractory Aggressive B-cell Lymphomas

National Cancer Institute (NCI)

Phase 2 Active not recruiting
54 enrolled 12 charts
Lymphoid

Plasmablastic Lymphoma, Burkitt Lymphoma, Lymphomatoid Granulomatosis, Lymphoma, B-Cell, Lymphoma, Large B-Cell, Diffuse, Lymphoma, Primary Effusion

Data powered by HemOnc (CC BY 4.0) Colophon âš¡